TPST (Tempest Therapeutics) Ending Cash Position: $2.25 Mil (As of Mar. 2026)


TPST Tempest Therapeutics Inc TPST
32 GF Score
Price $1.07
! 1 Warning Sign
View Full Analysis

What is Tempest Therapeutics Ending Cash Position?

Tempest Therapeutics TPST -1.83% 32 Ending Cash Position is $2.25 Mil as of Mar. 2026. GuruFocus rates TPST with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Tempest Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was $2.25 Mil.

Tempest Therapeutics's quarterly Ending Cash Position increased from Sep. 2025 ($7.96 Mil) to Dec. 2025 ($8.15 Mil) but then declined from Dec. 2025 ($8.15 Mil) to Mar. 2026 ($2.25 Mil).

Tempest Therapeutics's annual Ending Cash Position declined from Dec. 2023 ($39.67 Mil) to Dec. 2024 ($30.71 Mil) and declined from Dec. 2024 ($30.71 Mil) to Dec. 2025 ($8.15 Mil).

Tempest Therapeutics Ending Cash Position Related Terms

Tempest Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Tempest Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tempest Therapeutics Ending Cash Position Chart

Tempest Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 51.83 31.60 39.67 30.71 8.15

Tempest Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.95 14.72 7.96 8.15 2.25
TPST
32GF Score
Tempest Therapeutics Inc TPST
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tempest Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Tempest Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=30.711+-22.561
=8.15

Tempest Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=8.15+-5.902
=2.25

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $2.25 Mil mean?
Tempest Therapeutics (TPST) has a Ending Cash Position of $2.25 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Tempest Therapeutics and its competitors.
Is Tempest Therapeutics' Ending Cash Position too high?
Tempest Therapeutics' current Ending Cash Position is $2.25 Mil. Overall, Tempest Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tempest Therapeutics' Ending Cash Position compare to HOWL and INTI?
Tempest Therapeutics' Ending Cash Position of $2.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Tempest Therapeutics and its competitors. Tempest Therapeutics's current Ending Cash Position is $2.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tempest Therapeutics stock overvalued right now?
Tempest Therapeutics (TPST) has a current Ending Cash Position of $2.25 Mil. The current Ending Cash Position is $2.25 Mil. Tempest Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Tempest Therapeutics (TPST), the current Ending Cash Position is $2.25 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tempest Therapeutics Business Description

Address 2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
32GF Score

Get the complete analysis for TPST

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.07
Price